InvestorsHub Logo
Followers 833
Posts 119916
Boards Moderated 17
Alias Born 09/05/2002

Re: DewDiligence post# 4825

Tuesday, 02/01/2022 7:04:10 PM

Tuesday, February 01, 2022 7:04:10 PM

Post# of 4867
GILD owes ViiV* $1.25B+_3% royalty on_US Biktarvy sales, as a result of a patent settlement:

https://www.gsk.com/en-gb/media/press-releases/gsk-announces-settlement-between-viiv-healthcare-and-gilead-sciences/

The 3% royalty is a pretty big deal since Biktarvy’s had annualized US sales of $8.4B(!) in 4Q21.

* ViiV is a JV comprised of: GSK (76.5%); PFE (13.5%); and Shionogi (10%).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent GILD News